Scientific Committee

1st World NET Forum

Susana Haydée Belli, ARGENTUM

Susana Haydée Belli is an Endocrinologist and Head of the Department of Endocrinology at Instituto Alexander Fleming, Buenos Aires, Argentina since 2004. She is a founding member of the Argentine Group of Neuroendocrine Tumors (ARGENTUM), which started in 2005, member of the Argentinian Endocrine Society and chief of the group for the study of adrenal diseases. Susana is also a member of the Advisory Board of the European Society of Neuroendocrine Tumors (ENETS) since 2018 and is currently involved in the development of the Clinical Practice Guidelines in GEP-NET in the National Academy of Medicine, Argentina. She has authored over 50 papers on endocrinology diseases and is an active speaker in national and international endocrinology events.

Emily Bergsland, NANETS

Dr. Emily Bergsland is a Professor of Medicine and holds the Ernest Rosenbaum, MD Endowed Chair of Medical Oncology. She received her medical degree from the University of Minnesota and completed her internship, residency, and chief residency in internal medicine at University of California, San Francisco (UCSF). She subsequently completed fellowships in Medical Oncology and Molecular Medicine before joining the UCSF faculty in 1998. A gastrointestinal oncologist, Dr. Bergsland is the Director of the UCSF Center for Neuroendocrine Tumors and leads a multi-disciplinary clinical and translational research team focused on neuroendocrine tumors (NETs). At a national level, Dr. Bergsland is Chair of the NET Task Force for the National Cancer Institute, Co-Chair of the North American Neuroendocrine Tumor Society (NANETS), and a member of the NCCN NET guidelines panel. She is also the principal investigator for a national study of pazopanib v placebo in patients with carcinoid tumors performed by the ALLIANCE for Clinical Trials and funded by the National Cancer Institute.

Jie Chen, CSNET

Professor Jie Chen is Deputy Director of the Department of Gastroenterology, the First Affiliated Hospital,Sun Yat-Sen University, Guangdong, China. Her main area of interest is digestive neuroendocrine tumors. As one of the pioneer experts for NETs in China, she focusses her attention on clinical and translational research in GEP-NETs. She founded the first Multidisciplinary Care Team for NETs in China in 2011 as well as the Chinese Study Group for Neuroendocrine Tumors (CSNET) in 2015. She is currently the Chair of CSNET. Her major areas of research interest are the therapeutic strategies of NETs and the development of biomarkers of diagnostic or therapeutic interest in NETs. She has published high-quality peer-reviewed papers in the NET field over the past nine years. She was an Advisory Board Members at European Neuroendocrine Tumor Society (ENETS) from 2015 to 2018. She joined the editorial board of Neuroendocrinology in 2019.

Massimo Falconi, ENETS
Prof. Massimo Falconi

Professor Massimo Falconi, MD is currently Full Professor of Surgery and Chairman of the Pancreatic Unit at the University Vita e Salute, San Raffaele Hospital IRCCS, in Milan, Italy. In addition to his new osition as the 2016 – 2018 Chairman of ENETS, Prof. Falconi is currently also on the executive committee of IAP. Furthermore, he is a member of the medical society EPC and EAHPBA.

He serves as Associate Editor for the section of the pancreas and neuroendocrine tumors for Digestive and Liver Disease, official journal of the Italian and French Gastroenterological societies. He is also editorial member of the following journals: World Journal of Gastroenterology, subject Area Editor of The International Journal of Biological Markers and of International Journal of Endocrine Oncology. He has an impact factor calculated on the basis of JCR 2013 of more than 1,400 and his h index on Scopus is 58.
He has written almost 300 peer-reviewed articles and currently reviews articles for the following publications: Annals of Oncology, British Journal of Surgery, Cochrane, Gut, Lancet, Neuroendocrinology, Nutrition, Pancreas, Pancreatology, Journal of Endocrinological Investigation (JEI), Journal Of the Pancreas (JOP), Surgery, Annals of Surgery.
Prof. Falconi studied medicine at the University of Verona, specializing in general surgery, gastroenterology and endoscopy. He has participated in international medical research projects in such diverse places as Germany, Spain, Ecuador and Japan.

Rodney Hicks, APNETS

Rod is a Professorial Fellow of the University of Melbourne, Director of Molecular Imaging and Therapeutic Nuclear Medicine at the Peter MacCallum Cancer Centre in Melbourne. His group has a strong focus on translational research. He first established peptide receptor radionuclide therapy in Australia in 1996. The Neuroendocrine Tumour Service, which he co-chairs, was recently certified as ENETS Center of Excellence. He has published more than 450 peer-reviewed articles. He is Editor-in-Chief of Cancer Imaging and on six other editorial boards, including Endocrine-related Cancer. He received a National Health and Medical Research Council Program Grant in 2013; in 2015, he received a NHMRC Practitioner Fellowship and was inducted as a Fellow of the Australian Academy of Health and Medical Science.

James Howe, NANETS

Dr. Howe is Director of the Division of Surgical Oncology and Endocrine Surgery, Co-Director of the Neuroendocrine Cancer Clinic and a Professor of Surgery at the University of Iowa Carver College of Medicine. He did his General Surgery residency at Washington University and Surgical Oncology fellowship at Memorial Sloan-Kettering Cancer Center. Past research activities included studies to identify the pre-disposing genes for MEN2A and Juvenile Polyposis. His current research efforts are directed towards understanding the genetics of neuroendocrine tumors, specifically looking for pre-disposing genes as well as using gene expression profiles to make diagnoses and identify new therapeutic targets. His clinical focus is on the surgical management of small bowel and pancreatic neuroendocrine tumors and their metastases.

B.A. Krishna, APNETS

Dr. B.A. Krishna is the Director of Nuclear Medicine and PET imaging at Lilavati Hospital and Research Centre, Mumbai, India. He has more than 40 years’ experience in nuclear imaging & thyroid cancer management and 14 years’ experience in imaging and therapy of neuroendocrine tumors.   In 2008, he set up the 177Lu-DOTA scan and therapy facilities using indigenously produced isotopes. His group presented the first data on using 177-Lu-DOTA scan as dosimetry scan prior to PRRT. In 2015, he has established NET center in Mumbai where multi-disciplinary NET clinics & PRRT facilities have been instituted. He hosted the 5th APNETS conference in 2017 in Mumbai. At this conference, i-NET (Indian NeuroEndocrine Tumor Group) was inaugurated. He is the co-coordinator of this group and has conducted three NET seminars in different parts of the country to propagate NET as a speciality in India.

Simone Leyden, INCA

Simone Leyden is the Co-Founder and CEO of the Unicorn Foundation Australia, which was established in 2009. In her role as CEO, Simone advocates for greater access to treatments and diagnostics, raises funds for the NET Nurse Support Service and research, produces resources and education materials about neuroendocrine tumors (NETs), and raises awareness about NET cancers within the medical community and public. Simone is an active member of many associations, including the current President and Communications Chair of the International Neuroendocrine Cancer Alliance (INCA), and has successfully convened NET-related medical conferences in Australia including the 4th World Theranostics Congress (2016), International Symposium on Pheochromocytomas and Paragangliomas (2017) and Asia Pacific Neuroendocrine Tumour Society (2018). Simone is passionate about improving the lives and outcomes of NET and rare-cancer patients around the world and bringing the patient voice to the forefront of research.

Toshihiko Masui, JNETS

Toshihiko Masui is Associate Professor in the Division of Hepatobiliary, Pancreatic Surgery and Transplantation in the Department of Surgery at Kyoto University, Kyoto, Japan. He is also the Secretary General for the Japan Neuroendocrine Tumor Society (JNETS).

Professor Masui’s general interests include the mechanisms of malignancy difference within NENs in basic science and the epidemiology of NEN in Japan. His current project elucidates how surrounding tissue supports the growth of NEN and clarifies the present status of NEN patients in Japan by using national registry.

Professor Masui was bestowed the Pancreatic Disease Research Encouragement Award in 2016.

Dermot O'Toole, ENETS
Dermot O'Toole

Dermot O’Toole is Professor in Gastroenterology and Clinical Medicine at Trinity College Dublin (TCD, The University of Dublin) and Consultant Gastroenterologist in St James’s and St Vincent’s University Hospitals Dublin. He graduated from TCD and has postgraduate degrees from TCD and the Universities of Paris and Angers. His major research interest is in gastrointestinal cancer biology especially in neuroendocrine tumour (NET)-related diseases and early GI neoplasia (Barrett’s oesophagus, gastric and colorectal cancers). Professor O’Toole is Clinical Lead for the national NET group. He has served on the executive committee of the European Neuroendocrine Tumours Society (ENETS) and is current President of ENETS helping to develop guidelines papers and standards of care initiatives in the field of NET. He is past Chair of the ENETS-driven European Centre of Excellence program. He has been involved in many national and international research activities in GI oncology and is a member of several professional bodies in Europe and North America serving as advisor on national health care projects/initiatives and on patient advocacy groups.

Marianne Pavel, ENETS
Prof. Dr. Marianne Ellen Pavel

Marianne Pavel is a Senior Physician and Chair of Endocrinology at the Friedrich-Alexander University of Erlangen, Germany, where she is heading the NET center, too. Her major focus in medicine for the last 20 years is neuroendocrine tumors. She is first author of the 2012 and the updated 2016 “ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary”. Board certified as a specialist in internal medicine in 2000, and endocrinology/diabetes in 2001, she was appointed as Vice Head of the Division of Endocrinology and Metabolism at the Friedrich-Alexander University Erlangen in 2001. She took a position as an Assistant Director at the Charité University Hospital in Berlin in 2007 and was conferred a Professorship for NET Disease at the Charité University in 2010. She has conducted numerous clinical trials in the field of NET and supports the activities of ENETS since 2005. In 2009, under her guidance, the NET Center at the Charité University was certified as one of the first ENETS Centers of Excellence. She is a member of the ENETS Executive Committee since April 2014 and has been elected as Chair of ENETS after 2020.

Aurel Perren, ENETS
Prof. Aurel Perren

Professor Aurel Perren, MD, is a Professor of Pathology at the University Bern. In addition to currently serving as ENETS Scientific Secretary, Professor Perren is also regularly involved in ENETS activities and task-force issues. He enriches multi-disciplinary discussions by bringing pathological and genetic viewpoints to the table. He has published in numerous scientific journals and is member of the editorial boards of Endocrine Pathology, Pathobiology, Virchows Archives and Endocrine-related Cancer.  His research focuses on the histopathological and genetic analysis of familial and sporadic NET with a special interest in pancreatic NET. He was involved in the WHO classification of endocrine tumors 2004 and has been involved since the first Frascati meeting in 2005.

Simron Singh, CommNETS

Dr. Singh is the Co-Head of the Susan Leslie Clinic for Neuroendocrine Cancers at the Odette Cancer Center in Toronto, Ontario – the largest of its kind in Canada.  He specialises in improving clinical outcomes as well as quality improvement in the care of patients with neuroendocrine cancers.  He is the Co-Chair of the Commonwealth Neuroendocrine Tumour research collaboration as well as the North American Neuroendocrine Tumor Society Annual Meeting Co-Chair. He has published extensively on NETs and holds numerous peer-reviewed grants to improve the care of patients with NETs. He has been invited extensively around the world to speak on improving disease outcomes in NETs. Dr. Singh is an Associate Scientist at the Institute for Clinical Evaluative Sciences in Toronto, Canada, as well as the Provincial Head of the Person Centered Care portfolio at Cancer Care Ontario.

Bertram Wiedenmann, ENETS
Prof. Bertram Wiedenmann

Bertram Wiedenmann is Professor of Internal Medicine and Gastroenterology and since 1997, is Head of the Department of Gastroenterology and Hepatology at Charité University Hospital in Berlin, Germany. He is a member of the Charité Supervisory Board since 2017. Following his discovery of synaptophysin (1985), his scientific interests focused on translational research in gastrointestinal oncology, specifically NET of the gastroenteropancreatic system. He was a Co-Founder of ENETS in 2004 and has also initiated the ENETS Centers of Excellence and developed the CoE Excellence Academy Fellowship Programme. He served from 2004 to 2006 as ENETS first Chairman and is its Treasurer since 2008. He is a member of several international and national societies. He is an Assistant Editor of the official ENETS journal, Neuroendocrinology, and member of several editorial boards. He has published in numerous leading scientific peer-reviewed journals. He has been Congress President 2016 of the German Society of Gastroenterology (DGVS), AGA Institute representative and Chair for the 2016-2017 Program Committee GI ASCO, Member of the Steering Committee GI ASCO 2018-2019.

Hong Zhao, CNETS

Professor Hong Zhao, M.D., works in the Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Science & Peking Union Medical College in China. He is also the Secretary General of Chinese Neuroendocrine Tumor Society (CNETS). His general scientific interests include gastroenteropancreatic neuroendocrine Tumors, hepatocellular carcinomas colorectal cancer liver metastases and abdominal surgery.

His current projects comprise genome sequencing analysis of gastric NEC and molecular mechanism research on colorectal cancer liver metastasis.

Professor Zhao has received the following honours:

  • 2015 Top 10 outstanding young physicians of the capital of China
  • 2014 Science and Technology Progress Award of Beijing City
  • 2013 HUAXIA Medical Science Prize

Scientific Committee

17th Annual ENETS Conference

Anne Couvelard

Anne Couvelard is Professor of Pathology at University of Paris and Head of the Department of Pathology in Bichat Hospital. Her main topics of research are pancreatic and neuroendocrine oncogenesis and the relationship between tumor progression, pathology and genetics. She is a member of ENETS since 2004; is an ENETS Advisory Board member since 2015; was elected to the board of the French Neuroendocrine Tumour Group (GTE) in 2010; is a member of the French Pathological Network for neuroendocrine tumors, “TENpath”, since 2011; she was involved in the 2017 WHO classification of endocrine organs. She has published more than 250 papers in international journals and is a reviewer for journals in the fields of pathology, oncology gastroenterology and endocrinology.

Massimo Falconi
Prof. Massimo Falconi

Professor Massimo Falconi is currently Full Professor of Surgery and Chairman of the Pancreatic Unit at the University Vita e Salute, San Raffaele Hospital IRCCS, in Milan, Italy. He is Vice-Chairman of ENETS and member of the Executive Committee at IAP. Furthermore, he is a member of EPC and EAHPBA. He serves as Associate Editor for the section of the pancreas and neuroendocrine tumors for Digestive and Liver Disease. He is also editorial member of World Journal of Gastroenterology, subject Area Editor of The International Journal of Biological Markers and of International Journal of Endocrine Oncology. He has written almost 300 peer-reviewed articles and currently reviews articles for the Annals of Oncology, British Journal of Surgery, Cochrane, Gut, Lancet, Neuroendocrinology, Nutrition, Pancreas, Pancreatology, Journal of Endocrinological Investigation (JEI), Journal Of the Pancreas (JOP), Surgery, and Annals of Surgery. Professor Falconi studied medicine at the University of Verona and specialised in general surgery, gastroenterology and endoscopy. He has participated in international medical research projects across the globe in diverse countries including Germany, Spain, Ecuador and Japan.

Nicola Fazio

Nicola Fazio was born in Campobasso, Italy. He graduated in 1988 from the University of L’Aquila, Italy, Faculty of Medicine and Surgery. In 1993, he specialised in internal medicine, in L’Aquila and in oncology in 2003 in Milan. In 2013, he gained a PhD in Digestive Oncology.

He is currently Director of the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors and Director of the Programme in Digestive and Neuroendocrine Tumors at the European Institute of Oncology, where he has been working since 1995. Since 2015, he is Head of the IEO ENETS Center of Excellence for GEP NETs. He served as ESMO Faculty Coordinator for Neuroendocrine, Endocrine and CUP from 2016 until 2019.

He was Chair of the ESMO NEN Preceptorship in 2017 and 2018 and he was invited to be Chair again in 2019. He was also asked to be chair of the ESMO NEN Advanced Course in 2019. Since 2013, he is Coordinator of the Italian (AIOM/ITANET) neuroendocrine neoplasms guidelines. He is member of the ENETS Advisory Board since 2015.

Rocio Garcia-Carbonero

Rocio Garcia-Carbonero is a medical oncologist with particular expertise in gastrointestinal neoplasias. She is an Associate Professor and coordinates the Gastrointestinal (GI) Tumor Unit at the Hospital Universitario Doce de Octubre in Madrid. She is a member of the ENETS Executive Committee and of the Spanish Society of Medical Oncology (SEOM). She is Deputy Chair of the ESMO e-learning and Continued Medical Education Working Group (ECMWG) and an active member of various scientific societies (ASCO, ESMO, ENETS, SEOM) and collaborative groups (EROTC, GETNE, TTD). She is a national leader in the field of neuroendocrine tumors, and is the current President of the Spanish co-operative group in NETs (GETNE). She is actively involved in clinical and translational research and is a member of the Scientific Advisory Group (SAG) for Oncology at the European Medicines Agency (EMA) since 2008. Her major areas of research interest include the development of new drugs or therapeutic strategies in the field of GI tumors, particularly NETs and colorectal cancer, and the development of biomarkers of diagnostic or therapeutic interest in this field. She has published more than 80 papers in peer-reviewed journals, as well as many book chapters.

Dermot O'Toole
Dermot O'Toole

Dermot O’Toole is Professor of Gastroenterology and Clinical Medicine at Trinity College Dublin (TCD, The University of Dublin) and Consultant Gastroenterologist at St James’s and St Vincent’s University Hospitals Dublin. He graduated from TCD and has postgraduate degrees from TCD and the Universities of Paris and Angers. His major research interest is in gastrointestinal cancer biology, especially in neuroendocrine tumor (NET)-related diseases and early GI neoplasia (Barrett’s oesophagus, gastric and colorectal cancers). Professor O’Toole is Clinical Lead for the national NET group. He has served on the executive committee of the European Neuroendocrine Tumor Society (ENETS) and is current Chairman of ENETS, helping to develop guideline papers and standards of care initiatives in the field of NET. He is past Chair of the ENETS-driven European Centers of Excellence programme. He has been involved in many national and international research activities in GI oncology and is a member of several professional bodies in Europe and North America, serving as advisor to national health-care projects/initiatives and to patient advocacy groups.

Marianne Pavel
Prof. Dr. Marianne Ellen Pavel

Marianne Pavel is a Senior Physician and Chair of Endocrinology at the Friedrich-Alexander University of Erlangen, Germany, where she is heading the NET center, too. Her major focus in medicine for the last 20 years is neuroendocrine tumors. She is first author of the 2012 and the updated 2016 “ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary”. Board certified as a specialist in internal medicine in 2000, and endocrinology/diabetes in 2001, she was appointed as Vice Head of the Division of Endocrinology and Metabolism at the Friedrich-Alexander University Erlangen in 2001. She took a position as an Assistant Director at the Charité University Hospital in Berlin in 2007 and was conferred a Professorship for NET Disease at the Charité University in 2010. She has conducted numerous clinical trials in the field of NET and supports the activities of ENETS since 2005. In 2009, under her guidance, the NET Center at the Charité University was certified as one of the first ENETS Centers of Excellence. She is a member of the ENETS Executive Committee since April 2014 and has been elected as Chair of ENETS after 2020.

Aurel Perren
Prof. Aurel Perren

Professor Aurel Perren, MD, is a Professor of Pathology at the University Bern. In addition to currently serving as ENETS Scientific Secretary, Professor Perren is also regularly involved in ENETS activities and task-force issues. He enriches multi-disciplinary discussions by bringing pathological and genetic viewpoints to the table. He has published in numerous scientific journals and is member of the editorial boards of Endocrine Pathology, Pathobiology, Virchows Archives and Endocrine-related Cancer.  His research focuses on the histopathological and genetic analysis of familial and sporadic NET with a special interest in pancreatic NET. He was involved in the WHO classification of endocrine tumors 2004 and has been involved since the first Frascati meeting in 2005.

John Ramage

Professor John Ramage is a Consultant Physician in Gastroenterology and Hepatology, Honorary Consultant Physician at the Institute of Liver Studies, King’s College Hospital and Lead Clinician for King’s Health Partners NET Centre which includes King’s, Guys and St Thomas’s, Kent Oncology Centre and Hampshire Hospitals. Professor Ramage was previously Research Director at Hampshire Hospitals Foundation Trust and is Head Clinician for the Hampshire Collaboration for Health Research and Education. Professor Ramage trained at Portsmouth, Brighton and King’s College hospitals. Professor Ramage is an ENETS Advisory Board member, past treasurer and immediate past Chair of the U.K. and Ireland Neuroendocrine Tumour Society. He is a member of the EORTC Quality of Life Group, through which he pursues research into quality of life in cancers. His main research interest is in quality of life and symptoms scores in neuroendocrine tumors of the small bowel and liver.  He has written more than 90 peer-reviewed publications and was the corresponding author of the UK guidelines for NETs.  He is now on the Executive Board of ENETS.

Eva Tiensuu Janson

Eva Tiensuu Janson is a Professor of Medicine and Senior Consultant in Endocrine Oncology at Uppsala University Hospital, Sweden. She serves as the Dean of the Medical Faculty at Uppsala University. She is also the Chair of the Nordic Neuroendocrine Tumor Group, a member of ENETS Advisory Board (since 2015) and of ENETS Executive Committee (since 2016). She is active in the Swedish group for endocrine abdominal tumors and has participated in the development of a national caring programme for abdominal neuroendocrine tumors (NETs) and a national quality registry for NETs. She obtained her PhD in 1995 on SI-NETs and has published about 120 papers on neuroendocrine tumors. Her research interest is tumor biology and genetics behind the development of neuroendocrine tumors, with a focus on hereditary SI-NETs and on the highly malignant G3 neuroendocrine neoplasms. She has participated in many clinical trials and has organised numerous scientific meetings and educational activities in the NET area with a special focus on young scientists and clinicians.

Bertram Wiedenmann
Prof. Bertram Wiedenmann

Bertram Wiedenmann is Professor of Internal Medicine and Gastroenterology and since 1997, is Head of the Department of Gastroenterology and Hepatology at Charité University Hospital in Berlin, Germany. He is a member of the Charité Supervisory Board since 2017. Following his discovery of synaptophysin (1985), his scientific interests focused on translational research in gastrointestinal oncology, specifically NET of the gastroenteropancreatic system. He was a Co-Founder of ENETS in 2004 and has also initiated the ENETS Centers of Excellence and developed the CoE Excellence Academy Fellowship Programme. He served from 2004 to 2006 as ENETS first Chairman and is its Treasurer since 2008. He is a member of several international and national societies. He is an Assistant Editor of the official ENETS journal, Neuroendocrinology, and member of several editorial boards. He has published in numerous leading scientific peer-reviewed journals. He has been Congress President 2016 of the German Society of Gastroenterology (DGVS), AGA Institute representative and Chair for the 2016-2017 Program Committee GI ASCO, Member of the Steering Committee GI ASCO 2018-2019.